Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lou Fehrenbacher"'
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Lou Fehrenbacher, John M. Robertson, Joseph M. Unger, Jennifer R. Klemp, Kristine Rinn, Danika L. Lew, Christine L. Sardo Molmenti, Vicky A. Newman, Robert S. Krouse, Zaixing Shi, Heather Greenlee, Kathy S. Albain, Judith Korner, Antoine Sayegh, Julie R. Gralow, Dawn L. Hershman, Sheri J. Hartman, Lisa Hansen, Shelly S. Lo, Carol J. Fabian
Publikováno v:
Obesity. 26:1539-1549
Objective This study aimed to test the feasibility of a 12-month weight loss intervention using telephone-based counseling plus community-situated physical activity (PA) in female breast cancer (BC) and colorectal cancer (CRC) survivors. Methods This
Autor:
Karen Axelsson, Jeanne Darbinian, Rhona Chen, Laurel A. Habel, Lou Fehrenbacher, Sharon B. Chang, Sherry Butler, Gillian Kuehner
Publikováno v:
Annals of surgical oncology. 26(6)
There is no consensus regarding the management of benign papillary breast lesions diagnosed on image-guided core needle biopsy (IGCNB). This is a retrospective review of 407 patients within Kaiser Permanente Northern California diagnosed between 2012
Autor:
Derick H Lau, Leonid L. Yavorkovsky, Howard West, David R. Gandara, Minh Huynh, Primo N. Lara, Michael Russin, Desiree S. Goldstein, G. Q. Chen, Lou Fehrenbacher
Publikováno v:
Journal of Clinical Oncology. 27:1401-1404
Purpose The regimens of weekly irinotecan with platinum have been used for treatment of metastatic small-cell lung cancer (SCLC). We conducted a multi-institution phase II trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in pat
Autor:
Mark G. Kris, David H. Johnson, Pam Klein, Lou Fehrenbacher, Roy S. Herbst, Alan B. Sandler, Bruce E. Johnson, Vincent A. Miller, Robert C. Hermann, D. Ramies, Diane Prager, Xin Li, Hai T. Tran
Publikováno v:
Journal of Clinical Oncology. 23:5892-5899
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if
Publikováno v:
Clinical lung cancer. 9(1)
PURPOSE Brain metastasis occurs commonly in patients with small-cell lung cancer (SCLC). Herein, we report the efficacy of irinotecan and carboplatin in the treatment of brain metastases from SCLC. In addition, we review the existing data on chemothe